丁苯酞联合单唾液酸四己糖神经节苷脂钠治疗急性进展型脑梗死的疗效分析

目的探讨丁苯酞联合单唾液酸四己糖神经节苷脂钠治疗进展型脑梗死的临床疗效和安全性。方法40例急性进展性脑梗死患者,随机分为实验组和对照组,各20例。实验组给予丁苯酞联合单唾液酸四己糖神经节苷脂钠治疗,对照组给予单唾液酸四己糖神经节苷脂钠治疗。观察比较两组患者在治疗前治疗后美国国立卫生研究院卒中量表(NIHSS)评分、临床疗效、不良反应发生情况。结果入院当日,两组NIHSS评分比较差异无统计学意义(P>0.05);治疗第15天,两组NIHSS评分均低于入院当日,且实验组低于对照组,差异有统计学意义(P<0.05)。实验组临床治疗有效率为90.0%,对照组治疗有效率为60.0%;实验组临床治疗有效率明显高于对照组,差异有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论丁苯酞联合单唾液酸四己糖神经节苷脂钠能明显改善进展性脑梗死患者的神经缺损症状,且安全有效。

Clinical analysis of butylphthalide combined with sodium monosialotetrahexosylganglioside in the treatment of acute progressive cerebral infarction

Objective To discuss the clinical efficacy and safety of butylphthalide combined with sodium monosialotetrahexosylganglioside in the treatment of acute progressive cerebral infarction.Methods A total of 40 patients with acute progressive cerebral infarction were randomly divided into experimental group and control group,with 20 cases in each group.The experimental group was treated with butylphthalide combined with sodium monosialotetrahexosylganglioside,and the control group was treated with sodium monosialotetrahexosylganglio side.The National Institutes of Health stroke scale(NIHSS)score before and after treatment,clinical efficacy,and occurrence of adverse reactions were observed and compared between the two groups.Results On the day of admission,there was no statistically significant difference in NIHSS score between the two groups(P>0.05).At 15th day after treatment,the NIHSS score of the two groups were lower than the day of admission,and the experimental group was lower than the control group.The difference was statistically significant(P<0.05).The total effective rate of clinical treatment of the experimental group was 90.0%,which was 60.0%of the control group;the total effective rate of clinical treatment of the experimental group was obviously higher than that of the control group,and the difference was statistically significant(P<0.05).There was no statistically significant difference in incidence of adverse reactions between the two groups(P>0.05).Conclusion Butylphthalide combined with sodium monosialotetrahexosylganglioside can significantly improve the neurological deficit symptoms in patients with progressive cerebral infarction,which is safe and effective.